Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1960 2
1964 1
1971 1
1974 1
1986 1
2002 1
2004 1
2005 2
2006 10
2007 1
2008 4
2009 4
2010 3
2011 2
2012 6
2013 7
2014 6
2015 15
2016 17
2017 15
2018 6
2019 13
2020 22
2021 18
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

142 results
Results by year
Filters applied: . Clear all
Page 1
Gastric cancer.
Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Van Cutsem E, et al. Among authors: prenen h. Lancet. 2016 Nov 26;388(10060):2654-2664. doi: 10.1016/S0140-6736(16)30354-3. Epub 2016 May 5. Lancet. 2016. PMID: 27156933 Review.
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. Among authors: prenen h. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Drilon A, et al. Among authors: prenen h. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838015 Free PMC article.
The potential and controversy of targeting STAT family members in cancer.
Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C, Prenen H, Pauwels P, Trinh XB, Wouters A, Smits ELJ, Lardon F, van Dam PA. Verhoeven Y, et al. Among authors: prenen h. Semin Cancer Biol. 2020 Feb;60:41-56. doi: 10.1016/j.semcancer.2019.10.002. Epub 2019 Oct 9. Semin Cancer Biol. 2020. PMID: 31605750 Free article. Review.
Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer.
Bieniasz-Krzywiec P, Martín-Pérez R, Ehling M, García-Caballero M, Pinioti S, Pretto S, Kroes R, Aldeni C, Di Matteo M, Prenen H, Tribulatti MV, Campetella O, Smeets A, Noel A, Floris G, Van Ginderachter JA, Mazzone M. Bieniasz-Krzywiec P, et al. Among authors: prenen h. Cell Metab. 2019 Nov 5;30(5):917-936.e10. doi: 10.1016/j.cmet.2019.07.015. Epub 2019 Aug 22. Cell Metab. 2019. PMID: 31447322 Free article.
Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis.
Wenes M, Shang M, Di Matteo M, Goveia J, Martín-Pérez R, Serneels J, Prenen H, Ghesquière B, Carmeliet P, Mazzone M. Wenes M, et al. Among authors: prenen h. Cell Metab. 2016 Nov 8;24(5):701-715. doi: 10.1016/j.cmet.2016.09.008. Epub 2016 Oct 20. Cell Metab. 2016. PMID: 27773694 Free article.
Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation.
Virga F, Cappellesso F, Stijlemans B, Henze AT, Trotta R, Van Audenaerde J, Mirchandani AS, Sanchez-Garcia MA, Vandewalle J, Orso F, Riera-Domingo C, Griffa A, Ivan C, Smits E, Laoui D, Martelli F, Langouche L, Van den Berghe G, Feron O, Ghesquière B, Prenen H, Libert C, Walmsley SR, Corbet C, Van Ginderachter JA, Ivan M, Taverna D, Mazzone M. Virga F, et al. Among authors: prenen h. Sci Adv. 2021 May 7;7(19):eabf0466. doi: 10.1126/sciadv.abf0466. Print 2021 May. Sci Adv. 2021. PMID: 33962944 Free article.
MET is required for the recruitment of anti-tumoural neutrophils.
Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson AA, Wauters E, Walmsley S, Prenen H, Granot Z, Casazza A, Mazzone M. Finisguerra V, et al. Among authors: prenen h. Nature. 2015 Jun 18;522(7556):349-53. doi: 10.1038/nature14407. Epub 2015 May 18. Nature. 2015. PMID: 25985180 Free PMC article.
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Van Cutsem E, et al. Among authors: prenen h. J Clin Oncol. 2012 Oct 1;30(28):3499-506. doi: 10.1200/JCO.2012.42.8201. Epub 2012 Sep 4. J Clin Oncol. 2012. PMID: 22949147 Clinical Trial.
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.
Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Fakih MG, et al. Among authors: prenen h. Lancet Oncol. 2022 Jan;23(1):115-124. doi: 10.1016/S1470-2045(21)00605-7. Epub 2021 Dec 15. Lancet Oncol. 2022. PMID: 34919824 Clinical Trial.
142 results